Related Experiment Video
Updated: May 28, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?
Simon M Mueller1, Peter Itin, Peter Haeusermann
1Department of Dermatology, University Hospital Basel, Basel, Switzerland. muellersim@uhbs.ch
Abstract:
Cryopyrin-associated periodic fever syndrome (CAPS) is a rare inherited disease due to mutations in the NLRP3 (also called CIAS1) gene on chromosome 1q44 resulting in overproduction of interleukin-1. CAPS comprises three clinically overlapping disorders including Muckle-Wells syndrome. We report on two half-siblings with Muckle-Wells syndrome who were successfully treated with the interleukin-1 beta antibody canakinumab. Despite reduced dosing and longer treatment intervals compared to the recommended dosing schedule (e.g. 150 mg every 8 weeks), the efficacy and tolerability of canakinumab was impressive in both patients. The pharmacologic properties of canakinumab are reviewed and the clinical and economical aspects highlighted. We show that with individualized 'reflare-guided' administrations of canakinumab overall costs could hypothetically be reduced by 50% (approx. USD 60,000/patient/year) and therefore could have a major impact on treatment costs.
Insights
Cryopyrin-associated periodic fever syndrome (CAPS) treatment with canakinumab shows impressive efficacy and tolerability. Individualized dosing may significantly reduce treatment costs for this rare genetic disorder.
Area of Science:
- Genetics
- Immunology
- Pharmacology
Background:
- Cryopyrin-associated periodic fever syndrome (CAPS) is a rare inherited autoinflammatory disease.
- Mutations in the NLRP3 gene lead to interleukin-1 overproduction.
- Muckle-Wells syndrome is a subtype of CAPS.
Observation:
- Two half-siblings with Muckle-Wells syndrome were treated with canakinumab.
- Reduced dosing and longer intervals than standard were used.
- Treatment demonstrated impressive efficacy and tolerability.
Findings:
- Canakinumab effectively managed Muckle-Wells syndrome in the reported cases.
- Individualized, 'reflare-guided' administration of canakinumab was explored.
- This approach could potentially halve annual treatment costs (approx. USD 60,000/patient/year).
Implications:
- Canakinumab offers a promising therapeutic option for CAPS.
- Optimized dosing strategies can improve treatment accessibility.
- Reduced healthcare costs may enhance patient access to novel therapies.
Related Concept Videos
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dosage Regimen: Individualization
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Dosage Regimen: Multiple Oral Dosage
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Dosage Regimens: Partial Pharmacokinetic Parameters